The aim of present study was to formulate and evaluate self-microemulsifying drug delivery system containing piroxicam and to use the ability of porous magnesium alumina metasilicate as a solid carrier for self-microemulsifying drug delivery system. It was developed to resolve the problems of piroxicam such as low water solubility, low bioavailability and gastrointestinal irritation. Self-microemulsifying drug delivery system containing varying proportions of Capmul MCM, Cremophor EL and Transcutol-P were prepared and optimized using response surface methodology of Design-Expert ® software version 10. Liquid selfmicroemulsifying drug delivery systems were subjected to in vitro evaluation, including self-emulsification efficiency study, droplet size, zeta potential measurement and in vitro drug release studies. Solid selfmicroemulsifying drug delivery system was prepared by adding liquid self-microemulsifying drug delivery system with Neusilin US2 and filled in hard gelatin capsule. The optimized formulation consists of 28.26 % of Capmul MCM, 44.16 % of Cremophor EL and 27.58 % of Transcutol-P. The results showed that the drug release profile of piroxicam from the self-microemulsifying drug delivery formulations was higher than the pure piroxicam powder. The release of piroxicam was rapid and complete. Solid self-microemulsifying drug delivery systems after filled in hard gelatin capsule, predicted to be a promising technique to deliver a liquid formulation in solid dosage form.
Pattewar et al.: Self-microemulsifying Mouth Dissolving Film Self-microemulsifying drug delivery systems are widely used to address water-solubility issues of drug candidates, but with these systems, there is a chance of drug precipitation due to migration of the surfactant in the shell of capsule. Piroxicam is a class II drug that exhibits poor solubility and high permeability. Efforts were made to develop piroxicam self-microemusifying mouth dissolving fi lm using a polymer such as hydroxylpropyl methylcellulose as a fi lm-forming polymer and optimized using response surface methodology of Design-Expert® software version 10. A sublingual self-microemusifying mouth dissolving fi lm was prepared that disintegrated in 26 seconds. The in vitro drug release of self-microemusifying mouth dissolving fi lm was 98.04±0.016% in 5 min. The newly developed sublingual self-microemusifying mouth dissolving fi lm provided rapid absorption of piroxicam (t max ~2 h) and suitable for providing a rapid onset of analgesic action.
The aim of present study is to investigate the potential of nanostructured lipid carriers (NLCs) in improving the oral bioavailability of quetiapine fumarate, a second-generation antipsychotic drug. Quetiapine Fumarate (QF) loaded NLC were prepared by hot homogenization followed by an ultrasonication method. Response surface methodology - central composite design (CCD) was used to systemically examine the influence of concentration of capmul MCM EP, concentration of poloxamer 188 and concentration of egg lecithin on particle size (PS) and % entrapment efficiency (% EE) and to optimize the NLC formulation. The CCD consists of three factored design with five levels, plus and minus alpha (axial points), plus and minus 1 (factorial points) and the centre point. A mathematical relationship between variables was created by using Design Expert software Version 12. The statistical evaluations revealed that three independent variables were the important factors that affected the PS and % EE of QF loaded NLC. The best fitted mathematical model was linear and quadratic for PS and % EE respectively. The optimized formulations found with 218.1±0.14nm of PS and 93±0.16% of % EE. Results illustrated the superiority of developed QF loaded NLC formulation as a stable drug delivery system, providing better bioavailability with the possibility of better treatment for psychological disorders.
Bipolar disorder is psychological illness with periodic episodes of mania and depression. Schizophrenia is a complex mental disorder identified by delusions, hallucinations, disorganized behavior, impaired cognitive ability, disorganized speech and sudden change in personality. In both the diseases quetiapine fumarate (QF) drug is worth important in today’s scenario. This review gives complete QF drug profile along with mechanism of action. Quetiapine alone is successful for acute bipolar depression and the prevention of mania/hypomania switching. Literature survey section of this review gives information about quetiapine in different dosage form. By this review one can explore the scale up of quetiapine fumarate not only with immediate release and sustained release dosage form but also with novel drug delivery system like solid lipid nanoparticle and nanostructured lipid carrier.
Preparation of co-grinding mixture 22 Co-grinded mixture of drug and polymers were prepared in different ratio such as 1:1 to 1:9 w/ w. It was co-grinded for 5min, in ceramic mo rtar and sieved through 100 # mesh. ABS TRACT The enhancement of the oral bioavailability is currently one of the greatest challenges in the development of poorly water soluble drugs. The main objective of work to enhance solubility of Simvastatin (SIM) by use of natural polymer, chitosan (CHI) and Hydroxy propyl methyl cellulose E3LV (HPM CE3LV), synthetic polymer to produce cost effective formulation. Physical mixture, co-grinding method, spray drying method are compared for solubility enhancement of simvastatin. It is found that co-grinding method is best for solubility enhancement of simvastatin.Co-grinding method applied for preparation of drug polymer complex and compared with the solubility and dissolution of marketed preparation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.